Added to YB: 2026-10-08
Pitch date: 2026-10-06
INDV [bullish]
Indivior Pharmaceuticals, Inc.
-3.99%
current return
Author Info
No bio for this author
Company Info
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Market Cap
$4.2B
Pitch Price
$35.58
Price Target
N/A
Dividend
N/A
EV/EBITDA
7.71
P/E
13.00
EV/Sales
3.41
Sector
Pharmaceuticals
Category
special_situation
One Stock Discovered Using Michael Mauboussin’s ROIC Framework: Part 1 - Indivior Pharmaceuticals, Inc.
INDV (monitor): Indivior combines SUBLOCADE’s 76% share of long-acting injectables, 13.6% revenue growth and a Bloomberg-estimated 7.7x P/E on next year’s earnings with a proposed all-stock Supernus merger. Indivior holders would receive an $8.47 special dividend and own 56.5% of the combined company, with $125M of expected annual cost synergies. The case depends on SUBLOCADE retaining share and the merger securing shareholder and regulatory approval.
Read full article (7 min)